Syneos Health announced a major advancement in its AI-powered clinical ecosystem that embeds artificial intelligence directly into the core of drug development workflows, helping pharmaceutical companies navigate increasingly complex clinical trials faster and with fewer operational delays. By combining deep therapeutic expertise with modern AI technologies, the company is helping sponsors anticipate risks earlier and make faster, more informed decisions across protocol design, feasibility planning, enrollment, site activation, and monitoring.

What Is Syneos Health's AI Ecosystem and How Does It Work?

Syneos Health's differentiated approach focuses on integrating advanced AI capabilities into critical decision points throughout the clinical development lifecycle. Rather than deploying AI as a standalone tool, the company embeds intelligent systems directly into the workflows that matter most to trial teams. This integrated approach creates what the company calls a "unified intelligence environment" that brings together operational, clinical, and real-world data to enable faster, more confident decision-making.

The ecosystem combines three major technological partnerships and proprietary insights to deliver measurable improvements in trial performance. Each component addresses a specific bottleneck in the drug development process, from initial study design through final execution and monitoring.

How to Leverage AI Partnerships for Faster Clinical Development?

• Evidence-Based Protocol Development: Syneos Health partnered with Causaly, a company specializing in agentic AI for life sciences, to apply advanced scientific reasoning to protocol strategy and feasibility planning. Causaly's system surfaces evidence from a proprietary knowledge graph combining biomedical research and commercial insights. By accelerating the analysis of complex biomedical literature and emerging data, Syneos Health teams have reduced the time it takes to derive insights for study strategy and design by approximately 50%.
• Real-Time Operational Intelligence: Using Databricks' Data and AI Platform, Syneos Health created a continuous, near real-time view of clinical operations that reduces the time from source data capture to review-ready insight from days to hours. This acceleration enables faster intervention when problems arise and more efficient overall trial execution.
• Workflow Automation and Productivity: Building on a long-standing collaboration that began in 2023, Syneos Health integrated Microsoft Power Apps and other tools to develop more than 280 AI agents that integrate with Microsoft 365 Copilot. These agents improve productivity, streamline workflows, and support faster decision-making across the company.

The combination of these three partnerships creates a comprehensive ecosystem where AI handles routine analysis and data processing, freeing human experts to focus on strategic decisions and complex problem-solving. This human-centered approach ensures that AI augments clinical expertise rather than replacing it.

Why Does Speed Matter in Clinical Trial Development?

Clinical trials are among the most time-consuming and expensive components of bringing new drugs to patients. Delays in protocol development, feasibility assessment, and site activation can add months or years to the overall development timeline, increasing costs and delaying patient access to potentially life-saving therapies. By reducing the time required to analyze complex scientific literature and operational data, AI-powered systems help sponsors move faster without sacrificing quality or safety.

"Our priority is AI that works inside the complexity of clinical trials. By combining advanced AI with a deep understanding of sites, physicians, patients and the operational dynamics that shape trial performance, we're unlocking new opportunities for speed, clarity and quality," said Mike Montello, Chief Digital and Information Officer at Syneos Health.

Mike Montello, Chief Digital and Information Officer, Syneos Health

The 50% reduction in time required to derive insights for study strategy and design represents a significant competitive advantage for sponsors using Syneos Health's platform. This acceleration applies to one of the earliest and most critical phases of trial planning, where decisions made during protocol development can ripple through the entire study lifecycle.

How Does Governance Ensure Responsible AI Use in Regulated Healthcare?

Syneos Health emphasizes that its AI capabilities are deployed with strong human oversight and governance structures, ensuring responsible use in highly regulated healthcare environments. This approach acknowledges that while AI can accelerate analysis and decision-making, clinical development remains fundamentally a human endeavor where expert judgment, regulatory compliance, and patient safety must remain paramount.

"What differentiates Syneos Health is our ability to redesign how clinical development decisions are made through the combination of scientific intelligence, connected evidence, operational expertise and AI-enabled execution across the development lifecycle. By grounding AI in deep clinical expertise and real-world experience, we help sponsors reduce complexity, make better-informed decisions and ultimately deliver better outcomes for patients," stated Michael Brooks, Chief Operating Officer at Syneos Health.

Michael Brooks, Chief Operating Officer, Syneos Health

The emphasis on governance reflects broader industry recognition that AI in healthcare requires careful oversight. Rather than automating decisions, Syneos Health's ecosystem is designed to provide faster, more comprehensive information to human decision-makers, enabling them to make better choices more quickly. This human-in-the-loop approach balances the speed advantages of AI with the accountability and expertise required in regulated clinical development.

As pharmaceutical companies face mounting pressure to accelerate drug development while maintaining rigorous safety and efficacy standards, AI-powered ecosystems like Syneos Health's represent a significant shift in how the industry approaches clinical trials. By embedding intelligence directly into existing workflows and combining multiple specialized AI capabilities, the company demonstrates how technology can reduce operational friction without compromising the human expertise that remains central to bringing safe, effective therapies to patients.